Effect of combination therapy with hypothermia, magnesium and tirilazad in an experimental model of diffuse cerebral ischemia;Efecto de la hipotermia combinada con magnesio y tirilazad en un modelo experimental de isquemia cerebral difusa

Medicina Intensiva

Volumn 31, Issue 3, 2007, Pages 113-119

  Sanchez Casado M ^a,d   Sanchez Ledesma M J ^b   Goncalves Estella J M ^b   Abad Hernandez M M ^b   Garcia March G ^c   Broseta Rodrigo, J ^b  

^a HOSPITAL NUESTRA SEÑORA DEL PRADO   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

^d NONE   (Spain)

Author keywords

Cerebral ischemia; Hypothermia; Magnesium; Neuroprotection; Neuroprotectors; Tirilazad

Indexed keywords

MAGNESIUM SULFATE; TIRILAZAD;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CLAMP; ARTICLE; BODY TEMPERATURE; BRAIN ISCHEMIA; CAROTID ARTERY; CONTROLLED STUDY; CRYOTHERAPY; DIFFUSE CEREBRAL ISCHEMIA; DRUG EFFECT; HIPPOCAMPUS; HYPOTENSION; MEAN ARTERIAL PRESSURE; NEUROPROTECTION; NONHUMAN; RAT; REPERFUSION; WISTAR RAT;

EID: 34249936864     PISSN: 02105691     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0210-5691(07)74788-5     Document Type: Article

References (37)

1. Lipton P. Ischemic death cell in brain neurons. Physiol Rev. 1999;79:1431-568.
2. Curfman GD. Hypothermia to protect the brain. N Eng J Med. 2002;346:546.
3. Bartus RT, Dean RL, Mennerick S, Eveleth D, Lynch G. Temporal ordering of pathogenic events following transient global ischemia. Brain Res. 1998;790:1-13.
4. Muñoz-Torrero JJ, Mora FJ, Díez Tejedor E. Tratamiento específico del infarto cerebral agudo. Presente y futuro. Rev Neurol. 2000;30:959-82.
5. Schmid-Elsaesser R, Zausinger S, Hungerhuber E, Baethmann A, Reulen HJ. Monotherapy with dextromethorphan or tirilazad-but not a combination of both-improves outcome after transient focal cerebral ischemia in rats. Exp Brain Res. 1998; 122:121-7.
6. Schmid-Elsaesser R, Zausinger S, Hungerhuber E, Baethmann A, Reulen HJ. Neuroprotective effects of combination therapy with tirilazad and magnesium in rats subjected to reversible focal cerebral ischemia. Neurosurgery. 1999;44:163-72.
7. Schmid-Elsaesser R, Hungerhuber E, Zausinger S, Baethmann A, Reulen HJ. Combination drug therapy and mild hypothermia: a promising treatment strategy for reversible, focal cerebral ischemia. Stroke. 1999;30:1891-9.
8. Chopp M, Knight R, Tidwell CD, Helpern JA, Brown E, Welch KM. The metabolic effects of mild hypothermia on global cerebral ischemia and recirculation in the cat: comparison to normothermia and hyperthermia. J Cereb Blood Flow Metab. 1989;9:141-8.
9. Kavanagh RJ, Kam PC. Lazaroids: efficacy and mechanism of action of the 21-aminosteroids in neuroprotection. Br J Anaesth. 2001;86:110-9.
10. Miles AN, Majda BT, Meloni BP, Knuckey NW. Postischemic intravenous administration of magnesium sulfate inhibits hippocampal CA1 neuronal death after transient global ischemia in rats. Neurosurgery. 2001;49:1443-50; discussion 1450-1.
11. Shann F. Hypothermia for traumatic brain injury: how soon, how cold, and how long? Lancet. 2003;362:1950-1.
12. Muir KW, Lees KR. A randomized, double-blind, placebo-controlled pilot trial of intravenous magnesium sulfate in acute stroke. Stroke. 1995;26:1183-8.
13. Van der Worp HB, Kappelle LJ, Algra A, Bar PR, Orgogozo JM, Ringelstein EB, et al; TESS Investigators; TESS II Investigators. The effect of tirilazad mesylate on infarct volume of patients with acute ischemic stroke. Neurology. 2002;58:133-5.
14. Dube L, Granry JC. The therapeutic use of magnesium in anesthesiology, intensive care and emergency medicine: a review: [L'usage therapeutique du magnesium en anesthesiologie, reanimation et medecine d'urgence]. Can J Anaesth. 2003;50:732-46.
15. Muir KW, Lees KR. Dose optimization of intravenous magnesium sulfate after acute stroke. Stroke. 1998;29:918-23.
16. Altura BM, Altura BT. Interactions of Mg and K on cerebral vessels: Aspects in view of stroke-Review of present status and new findings. Magnesium. 1983;3:195-211.
17. De Courten-Myers GM, Myers RE, Schoolfield L. Hyperglycemia enlarges infarct size in cerebrovascular occlusion in cats. Stroke. 1988;19:623-30.
18. Auer RN. Combination therapy with U74006F (tirilazad mesylate), MK-801, insulin and diazepam in transient forebrain ischaemia. Neurol Res. 1995;17:132-6.
19. Blair JL, Warner DS, Todd MM. Effects of elevated plasma magnesium versus calcium on cerebral ischemic injury in rats. Stroke. 1989;20:507-12.
20. Izumi Y, Roussel S, Pinard E, Seylaz J. Reduction of infarct volume by magnesium after middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab. 1991;11:1025-30.
21. Marinov MB, Harbaugh KS, Hoopes PJ, Pikus HJ, Harbaugh RE. Neuroprotective effects of preischemia intraarterial magnesium sulfate in reversible focal cerebral ischemia. J Neurosurg. 1996;85:117-24.
22. Wolf G, Keilhoff G, Fischer S, Hass P. Subcutaneously applied magnesium protects reliably against quinolinate-induced N-methyl-d-aspartate (NMDA)-mediated neurodegeneration and convulsions in rats: Are there therapeutical implications. Neurosci Lett. 1990;117:207-11.
23. Siesjö BK. Pathophysiology and treatment of focal cerebral ischemia: part II. Mechanism of damage and treatment. J Neurosurg. 1992;77:337-54.
24. Thordstein M, Bagenholm R, Thiringer K, Kjellmer I. Scavengers of free oxygen radicals in combination with magnesium ameliorate perinatal hypoxic-ischemic brain damage in the rat. Pediatr Res. 1993;34:23-6.
25. Vaagenes P, Safar P, Moossy J, Rao G, Diven W, Ravi C, et al. Asphyxiation versus ventricular fibrillation cardiac arrest in dogs. Differences in cerebral resuscitation effects-a preliminary study. Resuscitation. 1997;35:41-52.
26. Lee EJ, Ayoub IA, Harris FB, Hassan M, Ogilvy CS, Maynard KI. Mexiletine and magnesium independently, but not combined, protect against permanent focal cerebral ischemia in Wistar rats. J Neurosci Res. 1999;58:442-8.
27. Milani H, Lepri ER, Giordani F, Favero-Filho LA. Magnesium chloride alone or in combination with diazepam fails to prevent hippocampal damage following transient forebrain ischemia. Braz J Med Biol Res. 1999;32:1285-93.
28. Mikami C, Suzuki M, Tsuiki K, Ogawa A. Effect of nicardipine and magnesium on cerebral infarction - brain surface perfusion technique. Cerebrovasc Dis. 2001;11:44-50.
29. Oktem IS, Menku A, Akdemir H, Kontas O, Kurtsoy A, Koc RK. Therapeutic effect of tirilazad mesylate (U-74006F), mannitol, and their combination on experimental ischemia. Res Exp Med (Berl). 2000;199:231-42.
30. Gross CE, Kimelberg HK, Raymond-Russell S, Booth C, Bednar MM. Delayed adjuvant therapy with the 21-aminosteroid U74006F and the anion channel blocker L644-711 does not improve outcome following thrombolytic therapy in a rabbit model of thromboembolic stroke. Surg Neurol. 1997;47:60-5; discussion 66-7.
31. Del Pilar Fernández M, Meizoso MJ, Lodeiro MJ, Belmonte A. Effect of desmethyl tirilazad, dizocilpine maleate and nimodipine on brain nitric oxide synthase activity and cyclic guanosine monophosphate during cerebral ischemia in rats. Pharmacology. 1998;57:174-9.
32. Hickenbottom SL, Grotta J. Neuroprotective therapy. Semin Neurol. 1998;18:485-92.
33. Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial) randomised controlled trial. Lancet. 2004;363:439-45.
34. Intravenous administration of magnesium in acute stroke: a randomized double-blind study. Clin Neuropharmacol. 2001;24:11-5.
35. Tirilazad for acute ischemic stroke. Cochrane Database Syst Rev. 2001;4:CD002087.
36. Tirilazad mesylate in acute ischemic stroke: A systematic review. Tirilazad International Steering Committee. Stroke. 2000;31:2257-65.
37. Grotta J. Neuroprotection is unlikely to be effective in humans using current trial designs. Stroke. 2001;33:306-7.